TABLE 4

CL_int,vivo of statins versus with CL_int determined by hepatocyte uptake, media loss, and metabolic stability assays

Data are presented as the mean ± S.E. for CL_int,vivo and CL_{int,hepatocyte uptake assay} and as the mean of two determinations for CL_{int,media-loss assay} and CL_{int,metabolic stability assay}.

	R_b	f_b	CL_int,vivo	CL_{int,hepatocyte uptake}	CL_{int,media-loss assay}	CL_{int,metabolic stability assay}
			ml/min/kg
Atorvastatin alone	1.2^a	0.047^a	851 ± 137	2480 ± 238	403	7.39
+Rifampicin	1.2^a	0.047^a	211 ± 35^b	663 ± 225^c	38.1	3.53
Pitavastatin alone	0.65^a	0.021^a	571 ± 40	2940 ± 327	347	1.23
+Rifampicin	0.65^a	0.021^a	91.6 ± 10.3^c	1040 ± 101^c	105	1.28
Pravastatin alone	0.59^a	1.2^a	41.8 ± 11.7	74.3 ± 17.7	34.4	9.29
+Rifampicin	0.59^a	1.2^a	9.95 ± 2.04	0.147 ± 11.211^b	7.16	2.06
Rosuvastatin alone	0.65^d	0.065^d	1480 ± 562	1040 ± 90	533	6.65
+Rifampicin	0.65^d	0.065^d	219 ± 20	276 ± 12^c	196	6.05
Cerivastatin alone	0.7^e	0.083^e	169 ± 26	2930 ± 934	262	0.336
+Rifampicin	0.7^e	0.083^e	24.2 ± 2.0^c	1310 ± 745	174	0.310
Fluvastatin alone	0.53^a	0.019^a	458 ± 35	705 ± 1070	194	2.90
+Rifampicin	0.53^a	0.019^a	98.9 ± 9.9^c	613 ± 572	136	<0

↵^a Watanabe et al., 2010.
↵^b P < 0.05 versus values in the absence of rifampicin.
↵^c P < 0.01 versus values in the absence of rifampicin.
↵^d Calculated from the PMDA-approved package data.
↵^e Calculated from the unbound fraction in the plasma (f_u,p) and the blood-to-plasma concentration ratio (R_b) data (Paine et al., 2008).